The conformation of abnormal prion protein (PrP Sc ) differs from that of cellular prion protein (PrP C ), but the precise characteristics of PrP Sc remain to be elucidated. To clarify the properties of native PrP Sc , we attempted to generate novel PrP Sc -specific monoclonal antibodies (mAbs) by immunizing PrP-deficient mice with intact PrP Sc purified from bovine spongiform encephalopathy (BSE)-affected mice. The generated mAbs 6A12 and 8D5 selectivity precipitated PrP
Introduction
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative disorders. They include scrapie in sheep and goat, bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeldt-Jakob disease in humans [1] . TSEs are characterized by the accumulation of an abnormal isoform of prion protein (PrP Sc ), which is generated by post-translational modification of the host-encoded cellular prion protein (PrP C ).
According to the protein-only hypothesis, PrP
Sc is the principal component of the infectious agent, the prion.
Conversion from PrP C to PrP Sc is a key event in the pathogenesis of prion diseases. PrP Sc has a larger number of bsheets and a lower a-helical structure content than PrP C [2] [3] [4] . These conformational changes facilitate the aggregation of PrP Sc and underlie its biochemical characteristics, such as insolubility to detergents and resistance to protease digestion [5, 6] . PrP Sc 's insolubility and tendency to aggregate have prevented its structural analysis. Although several PrP Sc models have been proposed [7] [8] [9] , the conformation of native PrP Sc is still obscure.
To discriminate PrP
Sc from PrP C , proteinase K (PK) digestion has been widely used. This process completely digests PrP C , whereas the C-terminal region of truncated PrP Sc remains, and these fragments are referred to as PrPcore, which is the only known disease-specific marker [10] . However, occasionally prion infectivity is not associated with a detectable PrPcore [11] . In addition, PrP Sc has been reported to consist not only of a proteaseresistant isoform but also of a protease-sensitive isoform [12] [13] [14] . These observations suggest an association between the PKsensitive PrP Sc (PrP Sc -sen) and prion infectivity [11] [12] [13] [14] . Characterization of PrP Sc -sen is important for understanding prion pathogenesis. However, PK digestion destroys not only the partial PrP Sc structure, but also the PrP Sc -sen molecule, and the precise properties of native PrP Sc , including PrP Sc -sen, remain to be elucidated. Analysis of native and intact PrP Sc is necessary to clarify the role of PrP Sc -sen in prion pathogenesis. PrP Sc -specific monoclonal antibodies (mAbs) are powerful tools for the analysis and isolation of the native PrP Sc . Several PrP Sc -specific monoclonal antibodies (mAbs) have been reported [15] [16] [17] [18] [19] [20] [21] . These mAbs distinguish PrP
Sc from PrP C without PK digestion. By using these mAbs, several PrP Sc -specific epitopes have been identified. Interestingly, these mAbs recognize different sub-regions or sequences as their epitopes. A panel of PrP Sc -specific mAbs will help elucidate the properties of native PrP
Sc . Here, we generated novel PrP
Sc -specific mAbs to analyze the properties of native and intact PrP Sc . PrP-deficient mice (PrP 0/0 ) were immunized with intact PrP Sc purified from BSE prionaffected mice. We examined the dynamics of native PrP Sc in prion-affected mice during the course of the disease using the generated antibodies.
Materials and Methods

Ethics Statement
Procedures involving animal subjects have been approved by the Institute Animal Care and Use Committee at the National Institute of Animal Health (approval ID: 09-44, 10-005 and 11-008).
Brain Samples
Mouse-passaged BSE and mouse-passaged scrapie strains ME7 and Chandler were used. These prions were routinely maintained by serial passage into wild-type mice (ICR; Japan SLC, Inc.) as described previously [22] [23] [24] . Brain samples from classical BSE (C-BSE) and scrapie-affected sheep were also used [25, 26] . Brains from diseased animals were removed and stored at 280uC for biochemical analysis or frozen in liquid nitrogen for histopathology.
Purification of Intact PrP Sc
Intact PrP
Sc was purified from the brains of BSE-affected mice in accordance with a protocol reported previously with minor modifications [20] . In brief, the brains of BSE-affected mice were homogenized in buffer containing 10% (w/v) sarkosyl, 10 mM Tris-HCl (pH 8.3), 1 mM EDTA, 133 mM NaCl, 1 mM DTT, 0.4 M 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (Pefabloc; Roche Diagnostics), and a protease inhibitor cocktail (Roche Diagnostics) using a multi-bead shocker (Yasui Kikai) and centrifuged at 1,0006g for 10 min at 4uC. The supernatant was centrifuged at 180,0006g for 150 min at 4uC. The pellet was resuspended in buffer containing 10% NaCl, 1% Zwittergent 3-14 (Calbiochem), 10 mM Tris-HCl (pH 8.3), 1 mM EDTA, 133 mM NaCl, 1 mM DTT, and 0.4 M Pefabloc. The sample was centrifuged at 250,0006g for 90 min at 20uC after sonication. The pellet was resuspended in buffer containing 10 mM Tris-HCl (pH 7.4), 5 mM MgCl 2 , and 100 mM NaCl and subsequently incubated with RNase A (100 mg/mL) and DNase I (20 mg/mL) for 2 h at 37uC. The sample was mixed with 20 mM EDTA, 10% NaCl, and 1% Zwittergent 3-14, loaded onto a 1 M sucrose cushion with 100 mM NaCl and 0.5% sulfobetaine, and then centrifuged at 250,0006g for 90 min at 20uC. Finally, the pellet was resuspended in PBS. The purity of intact PrP Sc was estimated using 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) with silver staining. The concentration of intact PrP Sc was estimated by BCA protein assay (Pierce).
Production of Monoclonal Antibodies
Five-week-old PrP 0/0 mice were immunized subcutaneously with 10 mg intact PrP Sc in complete Freund's adjuvant (Wako). The mice were boosted with 10 mg intact PrP Sc in incomplete Freund's adjuvant (Wako) twice at 14 day intervals. Three days before the cell fusion, mice were immunized intravenously with intact PrP Sc in PBS. Splenocytes obtained from the immunized mice were fused with mouse myeloma cells (Sp2/0-Ag14, DS Pharma Biomedical) with the standard protocol [27] . The hybridoma culture supernatants were screened by enzyme-linked immunosorbent assay (ELISA). MAbs were purified using a MAb Trap Kit (GE Healthcare), and the mAb subclasses were determined using an IsoStrip Mouse Antibody Isotyping Kit (Roche Applied Science).
Antibodies
The following mAbs against PrP were used in this study: mAb T2 [28] , 6H4 (Prionics), 31C6 [29] , and SAF32 (SPI-bio). MAb P2b (isotype: immunoglobulin (Ig) G2b), which recognizes a plantderived protein, was used as negative control. MAb binding was detected by horseradish peroxidase (HPR)-conjugated anti-mouse IgG. In some experiments, HRP-conjugated mAb T2 was used.
ELISA
The ELISA was performed according to a previously described method [20] . The ELISA plate (MaxiSorp, Nunc) was coated with Seprion ligand, which binds selectively to PrP Sc (Microsens Biotechnologies) [30] . After plates were blocked with 5% fetal bovine serum (FBS) in PBS, 100 mL samples of 0.1% (w/v) brain homogenate from BSE-affected mice in buffer containing 5 mM Tris-HCl (pH 8.3), 10% (w/v) sarkosyl, and 10% (w/v) Triton X-100 were added to the plates and incubated for 2 h at room temperature (RT). Seprion ligand-coated ELISA plates were considered to predominantly bind PrP Sc . The plates were washed with Tris-buffered saline (TBS) containing 50 mM Tris-HCl and 0.3 M NaCl. The plates were then treated with or without 4 M guanidine thiocyanate (GdnSCN) to generate denatured PrP Sc and native PrP Sc , respectively. The supernatant of each hybridoma was added to 2 wells (denatured and native PrP Sc ) and incubated for 1 h at RT. After washing in TBS containing 0.05% Tween-20, plates were incubated with HRP-conjugated anti-mouse IgG. The immunocomplex was detected using 3, 39, 5, 59-tetramethylbenzidine (TMB) as the substrate and analyzed by a microplate reader at 450 nm wavelength. MAb 6H4 was used as a positive control for ELISA. The ELISA values were compared between native and denatured PrP Sc .
Immunoprecipitation
Brain homogenate was mixed with buffer containing 0.01% Triton X-100, 0.01% sodium deoxycholate, 100 mM NaCl, 10 mM Tris-HCl (pH 7.6), protease inhibitor cocktail, and 0.4 M Pefabloc for a final concentration of 5% (w/v). After sonication, the sample was centrifuged at 5006g for 15 min at 4uC, and the supernatants were collected. The brain homogenates were diluted to final concentrations of 0.01-0.1% (w/v) with buffer containing 3% Tween 20 and 3% Triton X-100 in PBS. Protein-G Dynabeads (Dynal Biotech) were blocked with 4% (w/v) blocking solution (Block Ace; Yukijirushi). Brain homogenate samples (250 mL) were incubated with mAbs at concentrations of 1 mg/mL in 500 mL reaction volumes for 1 h at RT with rotation. Protein-G Dynabeads (20 mL) were then added and incubated for 1 h at RT on a rotator. The beads were washed 7 times with PBS containing 2% Tween 20 and 2% Triton X-100. To determine the PK resistance of the precipitated PrP, beads were treated with 50 mg/mL of Proteinase K (Roche Diagnostic) and incubated for 1 h at 37uC. PK digestion was terminated with 2 mM Pefabloc. The beads were resuspended in gel-loading buffer containing 2% (w/v) SDS and boiled for 10 min. Eluted PrP was detected by western blotting (WB). To examine the immunoreactivity of mAbs against PrPcore, brain homogenates were treated with 50 mg/mL of PK. Digestion was terminated by the addition of 2 mM Pefabloc, and the homogenate was immunoprecipitated. For the analysis of mAb immunoreactivity against denatured PrP Sc , brain homogenate samples were treated according to a previously described method with minor modification [31, 32] . Briefly, brain homogenate samples were mixed with an equal volume of 2% (w/ v) SDS and boiled for 10 min. Samples were then diluted in PBS for a final SDS concentration of 0.04% and subjected to the immunoprecipitation described above.
Western Blotting
The samples were separated by 12% SDS-PAGE and blotted electrically onto a PVDF membrane (Millipore). The blotted membrane was incubated with HRP-conjugated mAb T2 at RT for 1 h. Signals were developed with a chemiluminescent substrate (SuperSignal; Pierce Biotechnology).
PepSpots Analysis
Epitope analysis was performed according to a previously described method [33] . Briefly, mAbs were incubated with a gridded array of peptides comprising 122 polypeptides of 13 Figure 1 . Immunoreactivity of mAbs 6A12 and 8D5 in immunoprecipitation assays. Brain homogenate was incubated with mAb and immunoprecipitated with protein G-coupled magnetic beads. Immunoprecipitated sample was subjected to western blotting and detected by using HRP-conjugated mAb T2. MAbs 6H4 and SAF32 were used as positive controls. MAb P2b, which is isotype-matched with mAbs 6A12 and 8D5, was used as a negative control amino acids, shifted by 2 amino acids and covering the entire mouse PrP sequence. The peptides were covalently attached at their COOH-termini to a cellulose membrane as individual spots (JPT Peptide Technologies). Peptide-antibody complexes were detected using HRP-conjugated anti-mouse IgG and chemiluminescent substrate.
Peptide Competition Assay
Peptide sequences were obtained from mouse PrP sequence. Two peptides, P31-39 (WNTGGSRYP, amino acid sequence positions 31-39 of PrP) and P41-47 (QGSPGGN, positions 41-47 of PrP), were synthesized for peptide competition assays. To examine the specific reactivity of the antibodies to PrP Sc , mAbs were incubated with or without 200 mg/mL of synthetic peptide for 16 h at 4uC. Then, antibody-peptide combinations were mixed with the brain homogenate sample [0.05% (w/v)] from BSEaffected mice and immunoprecipitated as described above. Immunoprecipitated sample was subjected to western blotting, and signals were developed with HRP-conjugated mAb T2 and chemiluminescent substrate.
Histoblot Analysis
Histoblot analysis was performed as described previously [33] . Mouse brains were frozen in liquid N 2 and then cut into 5 mm sections. The sections were placed on glass slides and immediately pressed onto PVDF membranes. The membranes were thoroughly air-dried and stored at 280uC until use. The blotted membranes were incubated with mAbs. The mAb P2b was used as a negative PrPcontrol, and mAb 31C6 was used as a positive control. MAb binding was detected using HRP-conjugated anti-mouse IgG and chemiluminescence, as described for western blotting.
Immunohistochemical Analysis
Cryosections with a thickness of 5 mm were fixed with acetone for 10 min and incubated with mAbs without antigen retrieval pretreatment. Immunostaining was performed using a Histofine MAX-PO (M) Kit (Nichirei) with 3, 39-diaminobenzidine tetrachloride as the chromogen. The sections were then counterstained with hematoxylin.
Time Course Analysis
The brains of BSE-affected mice were homogenized in 9 volumes of PBS using a multi-bead shocker (Yasui Kikai) and centrifuged at 1,0006g for 5 min at RT. The supernatant was then intracerebrally inoculated into female 3-week-old wild-type mice. Mice were sacrificed at 0, 40, 80, and 120 days post-inoculation (dpi) and at the terminal stage (150 days). The brain homogenate [0.05% (w/v)] of each mouse was subjected to western blotting and immunoprecipitation as described above. 
Specific Immunoreactivity of mAbs 6A12 and 8D5 to PrP Sc
We performed immunoprecipitation assays to confirm the immunoreactivity of the newly generated mAbs to native PrP Sc . The mAbs 6A12 and 8D5 precipitated PrP from the brains of BSE-affected mice [0.1-0.01% (w/v)], but not from those of unaffected mice [1-0.1% (w/v)] (Fig. 1) . In contrast, mAb 6H4 strongly recognized PrP from unaffected mice. One mAb, SAF32, which recognizes the octapeptide repeat region as an epitope, reacted equally to PrP in normal and BSE-affected mice (Fig. 1) . These results suggest that mAbs 6A12 and 8D5 selectively immunoprecipitated PrP
Sc from BSE-affected mice. The cross-reactivity of the newly generated mAbs to PrP Sc from other animal species was analyzed. The mAbs 6A12 and 8D5 also detected PrP Sc in the brains of ME7-and Chandler-affected mice ( Fig. 2A) , as well as PrP Sc in the brains of scrapie-affected hamsters (data not shown), C-BSE-affected cattle, and scrapie-affected sheep (Fig. 2B) . No PrP signal from healthy animals was detected (Figs. 2A, B) .
Immunoreactivity of mAbs 6A12 and 8D5 in Histopathology
In histoblot analysis, pan-PrP mAb 31C6 reacted with PrP from unaffected and scrapie-affected mouse brains. MAbs 6A12 and 8D5 demonstrated positive immunoreactivity in brains from scrapie-affected mice brain but not from unaffected mice (Fig. 3A) . In acetone-fixed tissue sections, mAb 31C6 reacted faintly with PrP from unaffected and scrapie-affected mice without antigen retrieval. MAbs 6A12 and 8D5 strongly reacted with PrP in scrapie-affected mice, but no signal was detected in unaffected mice (Fig. 3B) . These results indicate that mAbs 6A12 and 8D5 specifically react with PrP Sc in situ.
Epitope Analysis of mAbs 6A12 and 8D5
MAbs 6A12 and 8D5 recognized PrP Sc both in solution and in situ (acetone-fixed tissues). To elucidate the molecular basis for these observations, we determined the epitopes of these mAbs by a synthetic peptide assay (Fig. S1 ). MAb 8D5 recognized WNTGGSRYP, at amino acid positions 31-39. MAb 6A12 recognized QGSPGGN, at positions 41-47, and RYPNQVYY, at positions 155-162 (Figs. 4A and S1). To confirm the specific reactivity of the mAbs to PrP Sc , we next performed peptide competition assays. We synthesized peptides corresponding to PrP amino acids 31-39 (P31-39) and 41-47 (P41-47) . In the peptide competition assays, the homologous synthetic peptide completely blocked the reactivity of mAbs 8D5 and 6A12 to PrP Sc , while the heterogeneous peptide did not (Fig. 4B) . Further, mAbs 6A12 and 8D5 did not react with PK-digested brain homogenates, which contain PrPcore (Fig. S2) . MAb 6A12 also demonstrated faint immunoreactivity against PrP amino acids 155-162 (Figs. 4A and S1) in peptide spots. However, mAb 6A12 did not react with PrPcore (Fig. S2) , and the synthetic peptide (P41-47) eliminated the reactivity of mAb 6A12 to PrP Sc (Fig. 4B ). This suggests that PrP 155-162 is not essential to the immunoreactivity of mAb 6A12. We next immunoprecipitated denatured PrP Sc to examine the properties of the epitopes for mAbs 6A12 and 8D5 on PrP Sc . The brain homogenates of BSE-affected mice were pretreated with SDS (denatured PrP Sc ) prior to immunoprecipitation. The immunoreactivity of mAb 6H4 against PrP increased after SDS denaturation of the brain samples. MAb SAF32 reacted with PrP in both SDS-denatured and native brain homogenates. In contrast, the immunoreactivity of mAbs 6A12 and 8D5 against PrP Sc was markedly decreased by denaturation (Fig. S3) .
Characterization of PrP Sc Precipitated by mAbs 6A12 and 8D5
To clarify the characteristics of the mAbs, immunoprecipitated PrP Sc was treated with PK. To detect the PrP band in WB, we used mAb T2, which recognizes the PrPcore region. Without PK digestion, precipitated PrP Sc from BSE-affected mice exhibited an intense signal and a molecular weight consistent with that of intact PrP. In contrast, with PK treatment, precipitated PrP Sc from BSEaffected mice showed a shifted molecular weight consistent with that of the PrPcore, and its signal intensity was decreased (Fig. 5) . These results suggest that mAbs 6A12 and 8D5 isolate intact PrP Sc , including the PK-resistant isoform of PrP Sc , from prionaffected individuals.
Native PrP Sc Dynamics in Prion Disease
We successfully isolated native and intact PrP Sc by using the newly generated mAbs. Next, we examined the dynamics of native PrP Sc in BSE-affected mice over the disease time course using these mAbs. PrP Sc signals were detected at 80 dpi by routine Sc was treated with (+) or without (2) 50 mg/mL of PK for 1 h and then western blotted with mAb T2. PrP signals were detected by HRP-conjugated mAb T2. MAb P2b, which is isotypematched with mAbs 6A12 and 8D5, was used as negative control. The total amount of PrP and PrPcore in the brain homogenates used in this experiment was detected by routine western blotting (WB). PK treatment decreased the signal intensity of PrP, however, the typical three bands were detected. doi:10.1371/journal.pone.0058013.g005
western blotting (Fig. 6A) . In immunoprecipitation assays with mAb 6A12, the PrP Sc signal was detected at 80, 120, and 150 dpi (Fig. 6B) . The dynamics of PrPcore detected after PK digestion of 6A12-precipitated PrP Sc were similar to those of PrPcore detected by western blotting (Figs. 6A, B) . To estimate the amount of PrPcore relative to the amount of total PrP Sc , the signal intensity of 6A12-precipitated PrP Sc with PK digestion (PrPcore) was compared to that of 6A12-precipitated PrP Sc without PK digestion (total PrP Sc ). The ratios of PrPcore to total PrP Sc were 3.9:12.2, 15.4:57.7, and 27.0:100 at 80, 120, and 150 dpi, respectively (Fig. 6C) . Interestingly, the percentage of PrPcore was constant (27-30% of total PrP Sc ) throughout the course of the disease.
Discussion
To gain insight into native PrP Sc , we attempted to generate PrP Sc -specific antibodies by immunizing PrP-deficient mice with intact PrP
Sc from BSE-affected mice. With this approach, we obtained novel PrP Sc -specific mAbs, named 6A12 and 8D5, which recognized the PrP amino acids 31-39 and 41-47 as their epitopes, respectively. Interestingly, neither mAb recognized PrP C or SDS-denatured PrP Sc in solution. These results indicate that this region may be refolded or that another molecule may bind to PrP C in solution, thus burying the epitopes. In contrast, the primary sequence was exposed in PrP Sc in solution and in situ. Furthermore, mAbs 8D5 and 6A12 cross-reacted with PrP Sc of different animal species, indicating that a PrP Sc -specific epitope exists in the N-terminal region of PrP Sc that is conserved across prion strains and animal species.
Previously reported PrP Sc -specific mAbs recognize epitopes putatively located in the PrPcore or C-terminal region of PrP Sc [15, 17, 18, 20] . MAb 15B3 reacted specifically with PrP Sc by recognizing three different peptide segments (at 142-148, 162-170, and 214-226) between 2 PrP molecules [15] . MAb 6H10 recognized a conformational epitope on PrP Sc in the C-terminal region [18] . Furthermore, the PrP C -PrP Sc binding motif was identified on PrP Sc using genetically-produced PrP (mouse sequence residues 89-112 and 136-158) motif-grafted antibodies [34, 35] . Additionally, a YYR motif in PrP (human sequence residues 149-151, 162-164, and 225-227) was reported to be a conformation-selective linear epitope of PrP Sc [16] . In this study, we also identified a novel conformation-selective linear epitope in the N-terminal region of PrP Sc (mouse PrP 31-39 and PrP [41] [42] [43] [44] [45] [46] [47] . The N-terminal domain of PrP consists of positively charged amino acid sequences and an octapeptide repeat sequence [5] . The octarepeat domain may bind copper ions [36] and affect copper metabolism [37] . Extra octarepeats resulted in inherited prion diseases in humans [38] , and recombinant PrP containing additional octapeptide repeats displays detergent insolubility and resistance to PK digestion similar to PrP Sc [39] . It has reported that the N-terminus structure of PrP was changed with pathogenic mutations, and it has linked to the binding ability with glycosaminoglycan, which was thought to be involved in prion pathogenesis [40] [41] [42] . Furthermore, a recent report showed the presence of a PrP Sc -specific conformation in the octarepeat domain using trypsin digestion methods [43] . These results suggest that the N-terminal region of PrP Sc is important for prion pathogenesis. Recently, recombinant PrP phosphorylated at serine 43 was reported to exhibit a conformation change that conferred proteinase resistance and aggregate formation [44] . The epitope of PrP Sc -specific mAb 6A12 includes this residue, and this mAb will be a powerful tool with which to clarify the mechanism of this conformational change. PrP Sc -sen has been demonstrated by a conformation dependent immune assay [12, 45, 46] , cold PK digestion [47] , immunoblotting following biochemical purification [13, 14] , immunologic detection [48] , and thermolysin digestion [46, 49] . However, no information on the dynamics PrP Sc -sen throughout the disease time course has been previously reported. The time course experiment in the present study addressed this question. PrP Sc -sen is a proteasesensitive isoform of native PrP Sc [12] . Indeed, we observed a decrease in PrP Sc signal intensity after PK digestion, and this decreased signal intensity was thought to result from the disappearance of PrP Sc [49] and conformation-dependent immune assays [45, 46] . The present study estimated the proportion of PrP Sc -sen to be approximately 70%. In this study, we isolated PrP Sc -sen on the basis of a PrP Sc -specific epitope at the N-terminal region. The structural selection of PrP Sc by the mAb may account for the difference.
The BSE prion has different characteristics than scrapie. The molecular weight of PrPcore from BSE is smaller than that from scrapie, and this difference is thought to derive from their different structures and/or conformations [22] . In previous reports, scrapie mouse-PrP Sc -specific mAbs were generated by immunizing intact PrP Sc from scrapie mice [20] . In this study, we could not acquire BSE-PrP Sc -specific mAbs from mice immunized with intact PrP Sc . However, we identified a novel PrP Sc -specific epitope located at the N-terminal region of PrP. These findings suggest that multiple PrP Sc -specific epitopes exist on PrP Sc ; this approach could help establish a panel of PrP Sc -specific antibodies. PrP Sc -specific mAbs 6A12 and 8D5 are expected to be powerful tools for the analysis of native and intact PrP Sc , which will lead to advances in understanding the pathogenesis of prion diseases. Sc . Brain homogenates from BSE-affected mice were mixed with an equal volume of 2% (w/v) SDS and boiled. Sample were then diluted in PBS for a final SDS concentration of 0.04% (refolding), immunoprecipitated, and western blotted. The total PrP in each homogenate was detected by routine western blotting (WB). SDS (+): SDS-denatured brain sample; SDS (2): native brain sample. The immunoreactivity of mAb 6H4 against PrP was increased with SDS denaturation. MAb SAF32 reacted with PrP in both SDS-denatured and native brain homogenates. In contrast, the immunoreactivity of mAbs 6A12 and 8D5 against PrP Sc was markedly decreased by SDS denaturation. (TIF)
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